ASM Microbe 2017 (June 01-04, 2017, New Orleans, LA)
|Publication Type||Conference paper|
Fungal infections predominantly caused by Aspergillus spp. are the most common cause of morbidity in lung transplant recipients and occur in up to 35% recipients after lung transplantation. Today, many patients, before or after lung transplantation, receive prophylactic inhaled amphotericin B (AMB) to decrease the rate of fungal infection. However, numerous studies have suggested that these widely used antimycotics are losing their efficacy, especially in the immunocompromised. The aim of the present study was to investigate the potency of Mul-1867 as a prophylactic for fungal pneumonia.
We used clinical isolates of A. fumigatus from lung transplant recipients with cystic fibrosis. Two antifungal agents were tested: novel, broad-spectrum antimicrobial Mul-1867 (С426H852N204 * 60 HCl) and liposomal AMB. The minimal fungicidal concentrations (MFCs) were determined by the broth macrodilution method.
Mul-1867 exhibited effective antifungal activity against A. fumigatus with an MFC of 0.25 mg/L. AMB was less effective than Mul-1867 with an MFC of 8 mg/L.
In the current study, we found that a novel drug candidate, Mul-1867, exhibits effective antifungal activity in vitro and in vivo. Mul-1867 was found to be highly effective in both prophylaxis and treatment of fungal pneumonia.
|Year of Publication||2017|
|Journal||ASM Microbe 2017 (June 01–05, 2017, New Orleans, LA)|
© Copyright TGV-inhalonix 2016. All rights reserved.